Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)

Dr. Thomas H. Carter

Hematology Oncology
200 Hawkins Dr, 
Iowa City, IA 
Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
200 Hawkins Dr, 
Iowa City, IA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Thomas Carter is a Hematologist Oncology provider in Iowa City, Iowa. Dr. Carter is rated as an Experienced provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Acute Monoblastic Leukemia (AmoL), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloblastic Leukemia without Maturation.

His clinical research consists of co-authoring 19 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in IA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO

Locations

200 Hawkins Dr, Iowa City, IA 52242

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Suspended
Publish Date: September 05, 2025
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
An Open Label, Multicenter, Phase II Trial Testing Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
An Open Label, Multicenter, Phase II Trial Testing Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: June 02, 2022
Intervention Type: Procedure, Drug
Study Drug: Decitabine
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 2 Less Clinical Trials

19 Total Publications

Point-of-Care Ultrasound Diagnosis of Right Ventricular Rupture Post Cardiac Arrest After Thrombolysis in Myocardial Infarction.
Point-of-Care Ultrasound Diagnosis of Right Ventricular Rupture Post Cardiac Arrest After Thrombolysis in Myocardial Infarction.
Journal: Clinical practice and cases in emergency medicine
Published: August 19, 2018
Similar Doctors
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Guido J. Tricot
Hematology Oncology | Oncology
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Guido J. Tricot
Hematology Oncology | Oncology
200 Hawkins Dr, 
Iowa City, IA 
 (0.1 miles away)
319-356-2148
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Guido Tricot is a Hematologist Oncology specialist and an Oncologist in Iowa City, Iowa. Dr. Tricot is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma, Schnitzler Syndrome, and Bone Marrow Transplant. Dr. Tricot is currently accepting new patients.

Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Shobha R. Chitneni
Hematology Oncology | Hematology | Oncology
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Shobha R. Chitneni
Hematology Oncology | Hematology | Oncology

State University Of Iowa

1351 Kimberly Rd, Suite 100, 
Bettendorf, IA 
 (53.8 miles away)
563-355-7733
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients

Shobha Chitneni is a Hematologist Oncology specialist and a Hematologist in Bettendorf, Iowa. Dr. Chitneni is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). Her top areas of expertise are Intraductal Papilloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Paget Disease of the Breast, Osteosarcoma, and Bone Marrow Aspiration. Dr. Chitneni is currently accepting new patients.

Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Mario B. Sy
Hematology Oncology | Hematology | Oncology
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Mario B. Sy
Hematology Oncology | Hematology | Oncology

State University Of Iowa

1351 Kimberly Rd, Suite 100, 
Bettendorf, IA 
 (53.8 miles away)
563-355-7733
Languages Spoken:
English, Filipino
See accepted insurances
Accepting New Patients

Mario Sy is a Hematologist Oncology specialist and a Hematologist in Bettendorf, Iowa. Dr. Sy is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Intraductal Papilloma, Chronic Lymphocytic Leukemia (CLL), Paget Disease of the Breast, and Angiosarcoma. Dr. Sy is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Carter's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile